Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 7/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.53 |
| ▸ | PDE5A | O76074 | 1/20 | 0.46 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.45 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1580149 | 0.90 | PDE5A (0.49) | PDE4BGAAADORA1PDE5AMAP2K2 | |
| SCHEMBL1580444 | 0.83 | MAP2K1 (0.50) | PDE4BADORA1MAP2K2MAP2K1 | |
| SCHEMBL1580581 | 0.83 | MAP2K1 (0.49) | PDE4BGAAADORA1PDE5AMAP2K2 | |
| SCHEMBL1580752 | 0.82 | MAP2K1 (0.45) | MAP2K2MAP2K1 | |
| SCHEMBL582892 | 0.81 | PDE4B (0.70) | PDE4BGAAADORA1PDE5AMAPT | |
| SCHEMBL583328 | 0.79 | GAA (0.74) | PDE4BGAAADORA1MAPTSMN1; SMN2 | |
| SCHEMBL582644 | 0.77 | PDE4B (0.60) | PDE4BGAAADORA1PDE5AMAPT | |
| SCHEMBL587425 | 0.77 | PDE4B (0.60) | PDE4BGAAADORA1PDE5AMAPT | |
| SCHEMBL583379 | 0.76 | PDE4B (0.74) | PDE4BGAAADORA1 | |
| SCHEMBL6324607 | 0.75 | MAP2K1 (0.52) | PDE4BGAAADORA1MAP2K2MAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841462-B2 | Bicyclic heterocycles as MEK kinase inhibitors | GENENTECH, INC. | 2014-09-23 | — | — | US | disclosed |
| US-8841462-B2 | Bicyclic heterocycles as MEK kinase inhibitors | GENENTECH, INC. | 2014-09-23 | — | — | US | disclosed |
| US-20110190257-A1 | BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS | GENETECH, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190257-A1 | BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS | GENETECH, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2010003025-A1 | BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS | GENENTECH, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190257-A1 | BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS | MAP2K7, MAP3K1, MAP3K5 | PDE4B 1512/4885GAA 4093/4885ADORA1 4555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.